Citius Oncology reported a gross margin of 67.07% and a net margin of -597.40% for the quarter ended Jun 2026. These financial ratios cover 17 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2021 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||
| Gross Margin | 79.99% | 80.27% | 67.07% | ||||||||||||||
| EBT Margin | -133.61% | -1,609.84% | -604.58% | ||||||||||||||
| EBIT Margin | -133.17% | -1,716.17% | -583.54% | ||||||||||||||
| EBITDA Margin | -133.17% | -1,716.17% | -583.54% | ||||||||||||||
| Operating Margin | -133.17% | -1,716.17% | -583.54% | ||||||||||||||
| Net Margin | -140.31% | -1,595.98% | -597.40% | ||||||||||||||
| FCF Margin | -186.48% | -229.81% | -181.46% | ||||||||||||||
| Efficiency | |||||||||||||||||
| Inventory AverageInventory Avg. | 11.33M | 14.86M | 16.27M | 19.75M | 22.46M | 22.65M | 22.64M | ||||||||||
| Assets AverageAssets Avg. | 0.19M | 34.22M | 68.50M | 69.33M | 58.79M | 60.18M | 60.65M | 48.94M | 66.78M | 87.43M | 90.96M | 91.57M | 96.33M | 105.46M | 105.34M | 106.40M | |
| Invested CapitalInvested Cap. | 0.12M | 36.46M | 0.35M | 24.05M | 21.37M | 18.75M | 49.94M | 45.09M | 39.44M | 36.20M | 52.47M | 62.21M | 39.07M | 44.19M | |||
| Leverage & Solvency | |||||||||||||||||
| Interest Coverage RatioInterest Cover | -13.61 | -82.26 | -114.58 | -866.26 | -37.62 | ||||||||||||
| Debt Ratio | 1.03 | 0.75 | 0.02 | 0.03 | 0.03 | 0.05 | 0.04 | 0.04 | 0.04 | 0.08 | 0.03 | 0.04 | 0.03 | ||||
| Times Interest Earned | -13.61 | -82.26 | -114.58 | -866.26 | -37.62 | ||||||||||||
| Valuation | |||||||||||||||||
| Price to EarningsP/E | -630.84 | -475.75 | -125.24 | -156.21 | -5.48 | -5.27 | -12.36 | -8.60 | -57.96 | -33.93 | -15.32 | -2.17 | -7.70 | ||||
| Price to SalesP/S | 21.50 | 34.58 | 46.02 | ||||||||||||||
| Price to BookP/B | 94.31 | 472.28 | -0.05M | 3.77 | 32.49 | 2.64 | 4.44 | 2.16 | 1.99 | 1.87 | 9.61 | 3.78 | 1.45 | 1.63 | 1.70 | ||
| Enterprise Value | 32.30M | 93.20M | 94.57M | 96.05M | 738.42M | 52.17M | 75.33M | 99.46M | 82.29M | 66.54M | 311.25M | 165.61M | 77.50M | 55.02M | 52.18M | ||
| EV to EBIT | -630.03 | -473.90 | -124.92 | -161.11 | -194.35 | -5.42 | -12.87 | -8.91 | -62.94 | -35.15 | -14.76 | -1.92 | -5.99 | ||||
| EV to EBITDA | -630.03 | -473.90 | -124.92 | -161.11 | -194.35 | -5.42 | -12.87 | -8.91 | -62.94 | -35.15 | -14.76 | -1.92 | -5.99 | ||||
| Market Capitalization | 32.59M | 93.32M | 94.94M | 96.30M | 738.45M | 52.42M | 75.58M | 99.46M | 82.29M | 66.54M | 311.25M | 169.53M | 84.80M | 57.65M | 68.74M | ||
| Price to FCFP/FCF | -552.82 | -946.96 | -251.76 | -273.46 | -206.44 | -11.53 | -15.05 | -25.36 | |||||||||
| EV to FCF | -552.11 | -943.27 | -251.10 | -272.15 | -205.76 | -10.54 | -14.36 | -19.25 | |||||||||
| EV to CFO | -552.11 | -943.27 | -251.10 | -272.15 | -205.76 | -10.54 | -14.36 | -19.25 | |||||||||
| Return Ratios | |||||||||||||||||
| Return on Sales [ROS]ROS | -133.17% | -1,716.17% | -583.54% | ||||||||||||||
| Return on Capital Employed [ROCE]ROCE | -9.80% | -10.06% | -42.58% | -57.13% | -68.02% | -84.79% | -50.23% | -36.84% | -93.55% | -99.34% | |||||||
| Return on Invested Capital [ROIC]ROIC | -54.68% | -68.57% | -89.72% | -55.43% | -40.86% | -87.09% | -114.08% | ||||||||||
| Return on Assets [ROA]ROA | -9.71% | -25.16% | -60.07% | -40.36% | -42.10% | -37.24% | -25.71% | -22.41% | -40.36% | -43.30% |